,

Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants

Moderna and Pfizer BioNTech vaccines prime T cells to fight SARS CoV 2 variants - اثربخشی واکسن علیه گونه های جدید کرونا

Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

Their new study, published in Cell Reports Medicine, shows that both CD4+ “helper” T cells and CD8+ “killer” T cells can still recognize mutated forms of the virus. This reactivity is key to the body’s complex immune response to the virus, which allows the body to kill infected cells and stop severe infections.

Release date: 01 July 2021
Source: La Jolla Institute for Immunology